If you are looking to invest in the gene therapy space then the Ocugen Inc (NASDAQ: OCGN) stock could be the one to track at this point.
It is a penny stock and earlier this year, the eye disease gene therapy developer had some crushing setbacks as well. However, things took a highly positive turn after the company announced that it partnered with the Indian firm Bharat Biotech in relation to the coronavirus vaccine named Covaxin.
According to the terms of the deal, Ocugen will have the right to commercialize the product in the United States and more importantly, the company will retain as big as 45% of the total profits. This proved to be the major trigger behind the remarkable rally in the stock over the past months. However, it is now necessary for investors to consider if the stock can continue on its merry ways in the coming weeks. It might be a good idea to track any news related to Ocugen at this point.
Writing for business and finance publishers has become his passion over the last decades after he completed a master’s degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.